ArticleFrontiers in immunology2025
TACE-HAIC versus HAIC combined with TKIs and ICIs for hepatocellular carcinoma with a high tumor burden-a propensity-score matching comparative study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Retrospective Analysis of Hepatic Disease Burden and Progression in a Hospital-Based Romanian Cohort Using Integrated Cross-Sectional and Longitudinal Data (2019-2023).Journal of clinical medicine · 2026Article
- DEB-TACE-HAIC combined with donafenib and camrelizumab in the treatment of unresectable hepatocellular carcinoma: a multicenter retrospective study.Frontiers in immunology · 2026Article
- TACE-HAIC plus TKIs with/without PD-1 inhibitors for unresectable hepatocellular carcinoma: a propensity score matching study.Frontiers in oncology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The present study aimed to comparatively examine transarterial chemoembolization (TACE) plus hepatic arterial infusion chemotherapy (HAIC) in combination with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) versus HAIC alone in combination with TKIs and ICIs for efficacy and safety in individuals with high tumor burden (major portal vein tumor thrombosis [PVTT] Vp3-4 or/and tumors larger than 10 cm) hepatocellular carcinoma (HCC). Methods: Totally 363 inoperable HCC cases with high tumor burden administered TACE-HAIC plus TKI and ICI (TACE-HAIC combination group, n=119) or HAIC plus TKI and ICI (HAIC combination group, n=244) were recruited between October 2020 and January 2024, and propensity score matching (PSM) was utilized for matching patients. Overall survival (OS), progression-free survival (PFS), objective response (ORR), disease control (DCR) rates, and safety signals were assessed. Results: Following PSM (1:2), 87 cases in the TACE-HAIC combination group were matched to 143 cases in the HAIC combination group. Median OS (26.8 vs. 19.1 months, Conclusions: For HCC patients with high tumor burden, HAIC demonstrates comparable efficacy to TACE-HAIC both in combination with TKIs and ICIs. Therefore, HAIC should be the preferred local therapeutic strategy over TACE-HAIC in HCC patients with high tumor burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.